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a  b  s  t  r  a  c  t
Background:  There  is  some  controversy  about  the  effect  of  continuous  positive  airway  pressure  (CPAP)  on
the  incidence  of  cardiovascular  events  (CVE).  However,  the incidence  of  CVE  among  patients  with  both
obstructive  sleep  apnea  (OSA)  ans  resistant  hypertension  (HR)  has  not  been  evaluated.  Our  objective  was
to analyze  the  long-term  effect  of  CPAP  treatment  in  patients  with  RH  and  OSA  on  the  incidence  of  CVE.
Methods:  Multi-center,  observational  and  prospective  study  of  patients  with  moderate-severe  OSA  and
RH. All the  patients  were  followed  up every  3–6  months  and  the  CVE  incidence  was  measured.  Patients






been  prescribed  CPAP.
Results:  Valid  data  were  obtained  from  163 patients  with  64 CVE  incidents.  Treatment  with CPAP  was
offered  to 82%.  After  58 months  of follow-up,  58.3%  of  patients  were  adherent  to  CPAP.  Patients  not
adherent  to CPAP  presented  a  non-significant  increase  in the  total  CVE  incidence  (HR:1.6;  95%CI:  0.96–2.7;
p  = 0.07).  A  sensitivity  analysis  showed  that patients  not  adherent  to  CPAP  had  a significant  increase  in the
ular  events  (HR:  3.1;  CI95%:  1.07–15.1;  p  =  0.041)  and  hypertensive  crises  (HR:incidence  of  cerebrovascPlease cite this article in press as: Navarro-Soriano C, et al. Long-term Effect of CPAP Treatment on Cardiovascular Events
in Patients With Resistant Hypertension and Sleep Apnea. Data From the HIPARCO-2 Study. Arch Bronconeumol. 2020.
https://doi.org/10.1016/j.arbres.2019.12.006
5.1;  CI95%:  2.2–11.6;  p =  0.006),  but the  trend  went  in  the opposite  direction  with  respect  to  coronary
events  (HR:  0.22;  CI95%:  0.05–1.02;  p = 0.053).
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Conclusions:  In patients  with  RH  and  moderate-severe  OSA,  an  uneffective  treatment  with  CPAP  showed
a trend  toward  an  increase  in the  incidence  of CVE  (particularly  neurovascular  events  and  hypertensive
crises)  without  any  changes  with respect  to  coronary  events.
© 2019  The  Author(s).  Published  by Elsevier  España,  S.L.U.  on  behalf  of  SEPAR.  This  is an  open  access
article  under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Efecto  a  largo  plazo  del  tratamiento  de  la  presión  positiva  continua  en  las  vías
respiratorias  en  eventos  cardiovasculares  en  pacientes  con  hipertensión
resistente  y  apnea  del  sueño. Datos  del  estudio  HIPARCO-2
r  e  s  u  m  e n
Antecedentes:  Existe  cierta  controversia  sobre  el efecto  de  la presión  positiva  continua  en  las  vías  respi-
ratorias  (CPAP)  sobre  la  incidencia  de  eventos  cardiovasculares  (ECV).  Sin  embargo,  no  se  ha  evaluado  la
incidencia  de  ECV  en  los  pacientes  con  apnea  obstructiva  del sueño  (AOS)  e hipertensión  resistente  (HR).
Nuestro  objetivo  fue  analizar  el  efecto  a largo  plazo  del tratamiento  con  CPAP  en  pacientes  con  HR  y AOS
en la incidencia  de ECV.
Métodos:  Estudio  multicéntrico,  observacional  y  prospectivo  de  pacientes  con AOS y  HR.  Cada  paciente
acudió  a revisión  cada  3-6  meses  y  se  midió  la  incidencia  de  ECV.  Se compararon  los  pacientes  con buena
adherencia  a la  CPAP  (al  menos  4  h/día)  con  aquellos  con  mala  adherencia  o aquellos  a  quienes  no se  les
había  indicado  la CPAP.
Resultados:  Se  obtuvieron  datos válidos  de  163  pacientes  con  64 eventos  de  ECV.  Se  ofreció  tratamiento
con CPAP  al  82%.  Después  de  58  meses  de  seguimiento,  el  58,3%  de  los  pacientes  presentaron  buena
adherencia  a  la  CPAP.  Los  pacientes  con mala  adherencia  o  sin  prescripción  de  CPAP presentaron  un
aumento  no  significativo  en la  incidencia  total  de  ECV (HR:  1,6; IC  95%:  0,96-2,7;  p =  0,07).  Un  análisis  de
sensibilidad  mostró  que  los  pacientes  con  mala  adherencia  a  la  CPAP  tuvieron  un  aumento  significativo
en  la  incidencia  de  eventos  cerebrovasculares  (HR:  3,1;  IC 95%:  1,07-15,1;  p =  0,041)  y crisis  hipertensivas
(HR:  5,1;  IC 95%:  2,2-11,6;  p = 0,006),  pero  la tendencia  fue  en  la dirección  opuesta  con  respecto  a  los
eventos  coronarios  (HR:  0,22;  IC 95%:  0,05-1,02;  p =  0,053).
Conclusiones:  En  pacientes  con HR  y  AOS  moderada  o grave,  un  tratamiento  ineficaz  con  CPAP  mostró  una
tendencia  hacia  un  aumento  en la incidencia  de  ECV  (particularmente  eventos  neurovasculares  y crisis
hipertensivas),  sin  ningún  cambio  con respecto  a los eventos  coronarios.
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Obstructive sleep apnea (OSA) has demonstrated a negative
mpact on blood pressure (BP) readings1 and the incidence cardio-
ascular events (CVE).2 Various pathophysiological explanations
ave been offered for this association.3
Although it would be logical to suppose that the elimination
f these respiratory events by treatment with continuous positive
irway pressure (CPAP) would lead to a reduction in the incidence of
VE, the results in the literature are uneven. These results basically
epend on the type of methodology used, the type of CVE studied,
nd the type of population included in the study.4–16
Patients with resistant hypertension (RH) – defined as the
ypertension that remains uncontrolled despite the administra-
ion of three antihypertensive drugs, including a diuretic at optimal
oses or those that requires at least four drugs to be controlled –
resent a high cardiovascular risk,17–21 as well as a high prevalence
f OSA.22 CPAP treatment in these patients has proved capable of
ring down BP readings to a clinically significant degree,23,24 but no
tudy to date has demonstrated whether long-term CPAP treatment
esults in a reduction in CVE in these patients.
The objective of our study was to assess whether long-term
PAP treatment in patients with RH alters the incidence of CVE
both fatal and non-fatal).
aterial and methods
tudy designPlease cite this article in press as: Navarro-Soriano C, et al. Lo
in Patients With Resistant Hypertension and Sleep Apnea. Da
https://doi.org/10.1016/j.arbres.2019.12.006
This was an observational, multicenter (24 centers) and
rospective study of a series of patients diagnosed with RH who por  Elsevier  España,  S.L.U.  en  nombre  de  SEPAR.  Este  es un  artı́culo  Open
encia  CC BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
presented moderate-to-severe OSA (apnea–hypopnea index [AHI]
≥15 events/h). All the patients signed their informed consent to
participate. This study was approved by the ethics committee of
the main research center (number 48/2008. Hospital General Uni-
versitario de Valencia).
The HIPARCO randomized control trial study23
Throughout 2012–2013, 194 patients with a diagnosis of RH and
moderate-to-severe OSA were randomized to receive CPAP or con-
servative treatment over three months. Patients with antecedents
of cardiovascular risk factors were not excluded from the study
(Appendix 1).
Selection of the patients
All those patients who took part in the previously published
HIPARCO study (clinicaltrials.gov Identifier: NCT00616265) were
included in the present study (n = 194).23 Those patients with no
follow-up data on the incidence or otherwise of fatal or non-fatal
CVE were excluded.
Follow-up after the HIPARCO study
Once the HIPARCO study finished, the randomization of CPAP
treatment also came to an end; each individual sleep and hyperten-
sion unit decided whether or not the patients were suited to CPAPng-term Effect of CPAP Treatment on Cardiovascular Events
ta From the HIPARCO-2 Study. Arch Bronconeumol. 2020.
treatment or any changes in medical treatment. All the patients
eventually selected for CPAP treatment were subjected to a titration
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In any case, all the patients were followed up in their respective
leep and hypertension units every 3–6 months, depending on the
everity of their condition. Data on adherence to CPAP and anti-
ypertensive treatment were collected in the same way as in the
IPARCO study, along with data on clinical changes and incidence of
ew CVE. The exclusion criteria and possible changes in treatment
including antihypertensive treatment) were also reevaluated.
The diagnoses and dates of the various fatal or non-fatal CVE
eviewed on an individual basis at every medical consultation. They
ere taken into consideration only when objective proof of their
ccurrence was supplied by the corresponding specialists, either at
he time of their occurrence or after a review of electronic hospital
r out-patient records.
ain outcome measures
The main outcome was the incidence of new fatal or non-
atal CVE, including transient ischemic attack (TIA), stroke, acute
yocardial infarction (AMI), coronary revascularization, angina,
trial fibrillation, hypertensive crises, heart failure, and cardiovas-
ular death.
Secondary outcomes included a separate analysis of other
omposite and individual outcomes: 1. Neurological out-
omes (stroke + TIA + neurological death); 2. Heart outcomes
AMI + angina/revascularization + coronary death); 3 heart fail-
re; 4. Hypertensive crisis (defined as the elevation of systolic
P > 179 mmHg  or diastolic BP > 109 mmHg25; 5. Atrial fibrillation.
tatistical analysis
Continuous variables were expressed as mean (SD), while
ategorical variables were reported as absolute numbers and per-
entages. The normality of the distribution of variables was  tested
y means of the Kolmogorov–Smirnov test.
As no data are available on the incidence of CVE in RH patients,
ny difference in the incidence of CVE of at least 10% between the
PAP branches with and without adherence during the follow-up
as used to calculate the sample size. Calculating a 10% loss of
atients, a total incidence of 60 CVE was required to achieve a
tatistical power of 80% and an alpha error of 5%.
The characteristics of the groups that tolerated CPAP and those
hat did not (or were not prescribed it) were compared by means
f a Student T, U Mann–Whitney or Chi squared test, depending on
he type of variable and its distribution.
For each of the composite or individual CVE, the point of ini-
ial inclusion in the HIPARCO study, after confirmation of RH and
SA (in the case of non-prescription of CPAP), or the start of CPAP
herapy (in the case of the treatment group) were considered the
ntry point into the study. It was decided to end the follow-up in
une 2018, once the sample size required for total CVE (main out-
ome) was achieved. The follow-up period for composite outcomes
nded with the first appearance of one of the CVE on the list of
hose defined by the composite, while the analysis of each individ-
al CVE ended at the point at which the first CVE of this specific
ype occurred.
In order to compare the incidence of CVE, in both composite and
ndividual forms, between the group adherent to CPAP and non-
dherent (or non-prescription) group, the corresponding Kaplan
eier curves were constructed with a log-rank test for between-
roup comparison. Finally, a multivariate Cox analysis was used
or each endpoint to adjust for the variables that the researchers
onsidered clinically justified for the corresponding endpoint. APlease cite this article in press as: Navarro-Soriano C, et al. Lo
in Patients With Resistant Hypertension and Sleep Apnea. Da
https://doi.org/10.1016/j.arbres.2019.12.006
wo-sided p value of less than 0.05 was considered significant. Data
anagement and statistical analyses were performed using Stata,




Of the 194 initial patients, 31 patients lacked information about
their follow-up and so they were ruled out for the analysis, which
finally covered 163 patients (Fig. 1). CPAP was offered to 82% of the
patients. The average use of CPAP treatment during the follow-up
(objectively measured by the internal counter of every device) was
5.1 (1.8) h per night, with 95 patients (58.3%) using it at least 4 h per
night during the follow-up and 38% using it at least 6 h per night.
The mean CPAP pressure used was  9.1 (1.8) mmHg. The residual
AHI following the application of CPAP during the titration study
was 3.9 (3.4) mmHg. The patients were followed up for a median
of 58 months (interquartile range of 44–68 months). There were
12 deaths (7.4%; 10 of cardiovascular origin). There were no differ-
ences in terms of age, gender, clinical picture, cardiovascular risk
factors, number of antihypertensive drugs or polygraphic variables
between those patients who were offered CPAP (n = 134; 82%) and
those without prescription of this treatment (n = 29; 18%).
Table 1 shows the patients’ general characteristics, along with
the comparison between those who  tolerated CPAP and those who
did not (or were not prescribed it). The mean age was  57.8 (9.5)
years and 68.1% of the patients were male. BMI  was 33.7 (5), AHI
40.1 (18.8) (96.6% obstructive), and the mean Epworth score was
9.2 (3.8). The median (IQR) of antihypertensive drugs taken was
3 (3–4). No significant changes were observed in the BMI  over the
course of the follow-up (33.6 [5] vs 33.5 [5], p = 0.2]). Those patients
who tolerated CPAP treatment presented a significantly higher BMI
than the group that did not tolerate (or were not offered) CPAP.
There were no differences in any of the other variables that were
analyzed.
Long-term effect of CPAP on total cardiovascular events
A total of 64 first CVE were observed, 32 CVE in each of the group
studied in terms of adherence to CPAP. Those patients adherent to
CPAP tended to present a lower total incidence of CVE (Fig. 2), and
this remained the case after adjustment for clinically relevant con-
founders such as age, gender, and BMI  (HR 1.6 [IC95%: 0.96–2.7;
p = 0.07) (Table 2). Both a higher BMI  and a need for a greater num-
ber of antihypertensive drugs were significantly related to a higher
total incidence of CVE. The results did not significantly change when
5 or 6 h were used as cut-off points to define adherence to CPAP.
Long-term effect of CPAP on cerebrovascular events
There were 11 new cerebrovascular events, 8 in the group not
adherent to CPAP and 3 in the group adherent to CPAP. The lat-
ter patients presented a significant reduction in the incidence of
these events, even after adjustment for age, gender, and BMI  (HR
3.1 [1.07–15.1; p = 0.041) (Fig. 2, Table 3).
Long-term effect of CPAP on hypertensive crises
Similarly, a total of 31 hypertensive crises were observed (23 in
the non-adherent group), which represented a significant drop in
the group adherent to CPAP, even after adjusting for the initial val-
ues of MBP  (mean BP), number of antihypertensive drugs required,
age, gender, and BMI  (HR 5.1 (2.2–11.6; 0.006) (Fig. 2, Table 3).
Long-term effect of CPAP on ischemic heart disease eventsng-term Effect of CPAP Treatment on Cardiovascular Events
ta From the HIPARCO-2 Study. Arch Bronconeumol. 2020.
No significant differences were observed between the two
groups, however, in the total number of coronary events (12 in the
group adherent to CPAP and 2 in the non-adherent group) (HR 0.22
[0.05–1.02]; p = 0.053) (Fig. 2, Table 3).
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Exclusion:
     -n=31. Lack of cardiovascular event
                 information
163 patients
Finally included











(RH + AHI > 15 events/hour)
+
Fig. 1. Flow-chart. RH: Resistant hypertension; AHI: Apnea–hypopnea index; IQR: Interquartile range.
Table 1
Characteristics of the patients included and comparisons between those adherent to CPAP treatment and those who were not adherent to (or were not offered) CPAP.
Variable All patients (n = 163) CPAP > 4 h/d (n = 95) CPAP < 4 h/d (n = 68) p
Age, yrs 57.8 (9.5) 58.3 (9.6) 56.9 (9.4) 0.27
Men,  n, % 68.1% 66.3% 70.6% 0.56
BMI  33.7 (5) 34.6 (5) 32.6 (4.6) 0.01
ESS  9.2 (3.8) 9.2 (3.7) 9.4 (4) 0.71
Diabetes mellitus 39.9% 42% 37% 0.51
Dyslipidemia 51.5% 50.5% 53% 0.76
Number of antihypertensive drugs 3 (3–4) 3 (3–4) 3 (3–4) 0.49
Previous CVE 20.9% 21.1% 20.6% 0.94
AHI  40.1 (18.8) 41.3 (18.6) 38.5 (19.2) 0.34
Tsat90% 15.5 (18.1) 16.9 (18.8) 13.8 (17.2) 0.27
Mean  02 saturation 91.9 (4.1) 91.6 (4.8) 92.2 (2.8) 0.40
Residual AHI at titration 3.9 (3.4) 2.9 (3.3) 4.8 (3.3) 0.21
24  h SBP, mmHg  144.2 (11.9) 144 (12.1) 144.5 (11.8) 0.8
24  h DBP, mmHg  83.3 (10.4) 82.4 (10) 84.6 (11) 0.19
24  h MBP, mmHg 103 (9.3) 103 (9.1) 102.9 (9.5) 0.9
BMI: Body mass index; ESS: Epworth Sleepiness Scale; CVE: Cardiovascular events; AHI: Apnea–hypopnea index; Tsat90%: Night-time with oxygen saturation below 90%;
SBP:  Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MBP: Mean Blood Pressure.
Table 2
Cox regression. Factors associated with the presence of a new cardiovascular event (total number).
Variable Beta coefficient Standard error HR 95%CI p
Age, yrs 0.03 0.01 1 0.97–1.03 0.84
Gender −0.21 0.28 0.4 0.5–1.4 0.8










24  h-mean blood pressure 0.014 
Number of antihypertensive drugs 0.24 
CPAP  < 4 h/d 0.48 
ong-term effect of CPAP on other cardiovascular endpoints
Finally, no significant differences were observed between the
wo groups in the incidence of cardiac arrhythmias along the linesPlease cite this article in press as: Navarro-Soriano C, et al. Lo
in Patients With Resistant Hypertension and Sleep Apnea. Da
https://doi.org/10.1016/j.arbres.2019.12.006
f atrial fibrillation (5 in the group not adherent and 10 in the group
dherent to CPAP; HR 0.9) or in new diagnoses of heart failure (5
n the group not adherent to CPAP and 5 in the adherent group; HR
.3) (Fig. 2, Table 3). 1.1 0.99–1.04 0.31
 1.3 1.1–3.1 0.03
 1.6 0.96–2.7 0.07
Discussion
This the first study to analyze the long-term effect of CPAP
treatment on the incidence of CVE in patients with RH and OSA.ng-term Effect of CPAP Treatment on Cardiovascular Events
ta From the HIPARCO-2 Study. Arch Bronconeumol. 2020.
According to our results, no reduction was observed, after a follow-
up of approximately 5 years, in the overall incidence of CVE, even
after adjusting the results for clinically significant confounders.
Other notable findings were obtained, however: a significant drop
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Coronary events Heart failure Cerebrovascular events
Hypertensive crises Atrial Fibrillation
CPAP≥ 4 hrs/day
CPAP< 4 hrs/day
Fig. 2. Kaplan–Meier curves (comparison of curves: log-rank) for individual and composite cardiovascular events in the group adherent to CPAP versus the non-adherent
group.
Table 3
Cox regression. Factors associated with the presence of a new cardiovascular event (composite or individual).
Crude Adjusteda
Outcomes HR 95%CI p HR 95%CI p
Outcome 1. Hypertensive crises
CPAP < 4 h/day 5.9 1.9–17.7 0.002 5.1 2.2–11.6 0.006
24  h-MBP, mmHg  1.6 1.2–2.8 0.011 1.4 1.1–2.7 0.033
Outcome 2. Total cerebrovascular events
CPAP < 4 h/day 4.1 1.1–15.5 0.037 3.1 1.1–15.1 0.041
BMI,  kg/m2 1.7 1.3–2.6 0.019 1.4 1.1–2.7 0.021
Outcome 3. Total coronary events
CPAP < 4 h/day 0.27 0.06–1.2 0.085 0.2 0.05–1.02 0.053
Age,  years 1.3 1.2–1.4 0.007 1.3 1.2–1.4 0.009
Outcome 4. Heart failure
CPAP < 4 h/day 1.3 0.4–4.3 0.66 1.3 0.4–4.2 0.7
Age,  years 1.1 1–1.3 0.011 1.1 1–1.2 0.015
Outcome 5. Atrial fibrillation
CPAP < 4 h/day 0.9 0.3–2.6 0.83 0.9 0.3–2.6 0.8




















BP: Mean blood pressure; BMI: Body mass index.
a Adjusted: All the outcomes were adjusted for age, gender and BMI. Hyperte
ntihypertensive drugs.
n the number of hypertensive crises and cerebrovascular events
both fatal and not-fatal), and no changes in the incidence of coro-
ary events in the group adherent to CPAP.
The effect of CPAP treatment on the incidence of CVE is an issue
hat continues to arouse great controversy.4–16 In the studies that
e have analyzed, the results are dependent on various factors,
uch as the type of study (clinical trials are more negative); the
dherence to CPAP; the type of event (a positive effect of CPAP
s more usually found in cerebrovascular, as opposed to coronary
vents); and the type of population studied (CPAP tends to demon-
trate a more positive effect in studies that include patients who
ave suffered an stroke, or who have a high risk of doing so, than
n those that include patients who have had a coronary ischemic
vent, or have a high risk of doing so).16Please cite this article in press as: Navarro-Soriano C, et al. Lo
in Patients With Resistant Hypertension and Sleep Apnea. Da
https://doi.org/10.1016/j.arbres.2019.12.006
Our study, the first to be undertaken on the long-term effect of
PAP on patients with RH and a high risk of both cerebrovascu-
ar and cardiovascular events, seems to follow similar lines. Thus,
hereas no changes were observed in the overall incidence of CVE crises were also adjusted for 24 h-MBP (mean blood pressure) and number of
between the compared groups according to their adherence to
CPAP, there was  a difference between the overall incidence of coro-
nary events and cerebrovascular events. These results could have
various explanations. Firstly, the mechanisms regulating cerebral
and coronary circulation in response to intermittent hypoxemia
and its elimination could also be different in RH patients.26–32
Moreover, the effects of the different responses from the brain and
heart to a significant drop in BP after CPAP are not inconsiderable.
Sanchez de la Torre et al.33 found a significant variability in the BP
decrease experienced by RH patients with moderate-to-severe OSA
after CPAP treatment. A significant number of patients experience a
drop in BP of more than 10 mmHg, and it is possible to identify these
subjects via the use of biomarkers. Therefore, an additional hypoth-
esis that might contribute to explaining the results is that in thoseng-term Effect of CPAP Treatment on Cardiovascular Events
ta From the HIPARCO-2 Study. Arch Bronconeumol. 2020.
subjects with RH and OSA in whom CPAP treatment might lead to a
significant decrease in BP (especially if the antihypertensive medi-
cations are not subsequently optimized), there is a possibility of an
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atients might experience an excessive BP drop at some point dur-
ng the 24 h (a BP drop under coronary perfusion pressure). This
ight be similar to the effect of the increase in coronary events
hat has been reported when an excessive BP drop occurs with
rug treatment in subjects with high cardiovascular risk, known
s the “J-curve phenomenon”.34,35 However, the latter hypothe-
is is purely speculative. Finally, there is a possibility that patients
ith RH and untreated OSA may  achieve a status of protection from
oronary events because they have developed an ischemic precon-
itioning state which means that their myocardium has adapted to
ontinue functioning with a low level of oxygen. In contrast, this
reconditioning state is lost with the CPAP treatment.
On the other, the reduction in the incidence of hypertensive
rises – a known risk factor for a cerebrovascular event36 – observed
n patients adherent to CPAP suggests that CPAP could play a pro-
ective role. It is therefore possible that the collation of all CVE (both
oronary and cerebrovascular) for the composite that was  our pri-
ary outcome (combined with the fact that coronary events were
ore frequent) meant that our results did not ultimately favor the
roup adherent to CPAP.16
The main strength of the present study is that it is the first to
xamine the long-term effect of CPAP on a group with a high car-
iovascular risk, in this case RH, in a very well characterized series
f patients coming from a recognized clinical study.
As regards the limitations of our study, it obviously should be
tressed that it is not a clinical trial. Once the randomized HIPARCO
linical trial had come to an end,23 the randomization had to be
erminated for ethical reasons, as a clinically significant improve-
ent had been found in the BP readings. Therefore, although the
atients were closely followed up, the study became observational
nd prospective, and it compared the group that tolerated CPAP
ith the one that did not, with all the well-known limitations of
his methodology. Furthermore, although the total number of CVE
orresponded with the calculation of the sample size, this was not
rue of the number of individual CVE of each type; this could trigger
 type II error, and significant differences could go undetected when
hey are in fact present. This situation does, however, strengthen
he conclusion that well-tolerated CPAP in RH patients can pro-
ide protection against cerebrovascular events and hypertensive
rises, but this conclusion cannot be reached with regards to those
ssociations that did not prove significant. Moreover we  have no
nalyzed the impact of the changes in the antihypertensive treat-
ent or the adherence to this treatment during follow-up and we
ave not performed 24 h-ABPM or heart function measures at the
nd of follow-up in all patients. Finally, the adherence of CPAP was
easured at the end of the study, so there was no continuous mon-
toring that allowed us to observe different patterns of adherence
hat could have an impact on the results of the study.
In conclusion, in our series of patients with RH and OSA, well-
olerated long-term treatment with CPAP did not modify the total
ncidence of CVE, although we did observe different patterns in the
ncidence of cerebrovascular events and hypertensive crises (which
ere significantly reduced) and that of coronary events (which
ere unchanged).
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